Clinical trials: Neoplasms, Prostatic
Prostate Cancer
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
The purpose of this study is to measure the benefit of sorafenib in patients with a rising PSA after treatment with radiation therapy or surgery who are NOT receiving with androgen ablation therapy.
- Trial name
- NCT00694291
- Testing
- Sorafenib
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer, Prostate Adenocarcinoma
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer.
- Trial name
- NCT03246347
- Testing
- ADT+Docetaxel+Enzalutamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Castrate Resistant Prostate Cancer
Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients
The study has three parts. Part 1 is a dose escalation to investigate the safety and tolerability of ASP9521. Part 2 will evaluate the safety and tolerability and initial anti-tumor activity of ASP9521.
- Trial name
- NCT01352208
- Testing
- ASP9521
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 13 people
- Sponsor
- Astellas Pharma Inc
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
This study was to evaluate the safety and efficacy of dalcilide tablets in combination with AA-P in the treatment of subjects with high tumor burden mHSPC and to determine the second stage starting dose and progression-free…
- Trial name
- NCT06099990
- Testing
- dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
- Volunteers
- 660 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostatic Cancer
Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess and compare the clinical benefit rate in patients with metastatic castrate-resistant prostate cancer and poor prognostic factors treated with cabazitaxel or novel hormonal agents…
- Trial name
- NCT02254785
- Testing
- cabazitaxel, Abiraterone, Enzalutamide 160mg daily (oral)
- Where
- 15 sites in Australia, Canada
- Volunteers
- 120 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Evaluation of Clarity Ultrasound Guidance for Prostate Therapy
Radiotherapy (RT) is an important treatment for prostate cancer with over 10,000 men receiving RT per year in the UK. Prostate RT aims to deliver radiation dose to the prostate to kill cancer cells whilst minimizing the dose…
- Trial name
- Clarity-Pro (NCT02388308)
- Testing
- Clarity ultrasound
- Where
- United Kingdom
- Volunteers
- 61 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Cardiovascular Injury, Prostate Carcinoma
Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer
Learning about the impact of anti-androgen treatment has on cardiac function in patients with prostate cancer may help plan treatment and help patients live more comfortably.
- Trial name
- NCT02722525
- Testing
- Magnetic Resonance Imaging, Exercise Intervention, Perfusion Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Prostate Cancer
PET-CT/MRI in the Radiotherapy for Prostate Cancer
The trial is to explore new and effective techniques in the treatment of prostate cancer and evaluate the role of PET-CT / MRI played in radiotherapy.
- Trial name
- NCT02816840
- Testing
- PET-CT, PET-MRI
- Volunteers
- 90 people
- Sponsor
- Xuzhou Medical University
Glioma, Astrocytoma
Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas
As a part of molecular imaging, many PET tracers have been investigated in this regard. Those include 18F-FDG being glucose analogue, 18F-FLT representing nucleoside metabolism, and 18F-FDOPA, 18F-FET, 11C-MET as amino acids…
- Conditions
- Glioma, Astrocytoma, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT06241391
- Testing
- PSMA PET-CT
- Where
- India
- Volunteers
- 35 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Prostate Cancer
Selenium in Preventing Prostate Cancer
RATIONALE: Selenium supplements may stop or delay the development of prostate cancer in patients at high risk of prostate cancer. It is not yet known which dose of selenium may be more effective in preventing prostate cancer.
- Trial name
- NCT00978718
- Testing
- high-selenium baker's yeast, selenium
- Volunteers
- 700 people
- Sponsor
- University of Arizona
Ovarian Cancer, Breast Cancer
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Background: All cells go through cycles which allow them to divide. In normal cells, checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) (CHEK 2 (Chk1/2) stop cell division at various points to allow any damage to…
- Conditions
- Ovarian Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT02203513
- Testing
- LY2606368
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to…
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma
- Trial name
- NCT06099093
- Testing
- 18F-DCFPyl
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Biochemically Recurrent Prostate Cancer
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy…
- Trial name
- ARASTEP (NCT05794906)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 226 sites in United States, Australia and 21 more
- Volunteers
- 985 people
- Sponsor
- Bayer
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy
Improving Erectile Function and Quality of Life After Prostate Cancer Treatment
This is a research study of erectile dysfunction (ED) in men diagnosed with prostate cancer. 144 patients and partners will participate in the study.
- Conditions
- Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Simple Prostatectomy, Erectile Dysfunction
- Trial name
- NCT01996852
- Testing
- Cognitive-behavioral Meetings, sildenafil citrate, Vacuum Constriction Device
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
99mTc-P137 SPECT/CT in Prostate Cancer
Purpose: This study will take prostate specific membrane antigen (PSMA) as the targeting of radionuclide labeled molecular probe to explore the diagnostic efficacy of 99mTc-P137 radioactive probe in prostate cancer.
- Trial name
- NCT05672485
- Testing
- SPECT/CT imaging with 99mTc-P137 nuclide probe
- Where
- China
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
The purpose of this study is to evaluate the safety and efficacy of a combination of nivolumab, ipilimumab, cabazitaxel and carboplatin in men with neuroendocrine prostate cancer (NEPC) or other aggressive variants of prostate…
- Trial name
- CHAMP (NCT04709276)
- Testing
- Nivolumab, Ipilimumab, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Andrew J. Armstrong, MD
Breast Cancer, Pain
Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer
RATIONALE: An outpatient educational and behavioral skills training program may help patients with metastatic breast or prostate cancer live longer and more comfortably.
- Conditions
- Breast Cancer, Pain, Prostate Cancer
- Trial name
- NCT00002668
- Testing
- Observation, Educational Intervention and Behavioral Skills Training
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 13 people
- Sponsor
- Eastern Cooperative Oncology Group
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
This phase II trial tests how well risk based de-escalated hormone therapy (i.e., fewer treatments) with radiation works in treating patients with prostate cancer.
- Trial name
- NCT06369610
- Testing
- Abiraterone Acetate, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Mayo Clinic
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Castration-resistant Prostate Cancer
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT02207504
- Testing
- Crizotinib, Enzalutamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute